Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: Post-hoc analysis of a randomised, placebo-controlled phase II clinical trial
JournalAnnals of the Rheumatic Diseases
PublisherBMJ Publishing Group
MetadataShow full item record
AbstractObjectives: In the phase II FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses (FORWARD) study, sprifermin demonstrated cartilage modification in the total femorotibial joint and in both femorotibial compartments by MRI in patients with knee osteoarthritis. Here, we evaluate whether sprifermin reduces cartilage loss and increases cartilage thickness, independent of location. Methods: Patients were randomised 1:1:1:1:1 to three once-weekly intra-articular injections of 30 ?g sprifermin every 6 months (q6mo); 30 ?g sprifermin every 12 months (q12mo); 100 ?g sprifermin q6mo; 100 ?g sprifermin q12mo; or placebo. Post-hoc analysis using thinning/thickening scores and ordered values evaluated femorotibial cartilage thickness change from baseline to 24 months independent of location. Changes were indirectly compared with those of Osteoarthritis Initiative healthy subjects. Results: Thinning scores were significantly lower for sprifermin 100 ?g q6mo versus placebo (mean (95% CI) difference: 334 ?m (114 to 554)), with a cartilage thinning score similar to healthy subjects. Thickening scores were significantly greater for sprifermin 100 ?g q6mo, 100 ?g q12mo and 30 ?g q6mo versus placebo (mean (95% CI) difference: 425 ?m (267 to 584); 450 ?m (305 to 594) and 139 ?m (19 to 259), respectively) and more than doubled versus healthy subjects. Conclusions: Sprifermin increases cartilage thickness, and substantially reduces cartilage loss, expanding FORWARD primary results. Trial registration number: NCT01919164. Copyright Author(s) (or their employer(s)) 2020.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85080941662&doi=10.1136%2fannrheumdis-2019-216453&partnerID=40&md5=a0fa62c390009a513b5072ceedb0c7e8; http://hdl.handle.net/10713/12244
- Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial.
- Authors: Hochberg MC, Guermazi A, Guehring H, Aydemir A, Wax S, Fleuranceau-Morel P, Reinstrup Bihlet A, Byrjalsen I, Ragnar Andersen J, Eckstein F
- Issue date: 2019 Oct 8
- Brief report: intraarticular sprifermin not only increases cartilage thickness, but also reduces cartilage loss: location-independent post hoc analysis using magnetic resonance imaging.
- Authors: Eckstein F, Wirth W, Guermazi A, Maschek S, Aydemir A
- Issue date: 2015 Nov
- Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial.
- Authors: Lohmander LS, Hellot S, Dreher D, Krantz EF, Kruger DS, Guermazi A, Eckstein F
- Issue date: 2014 Jul
- Structural effects of sprifermin in knee osteoarthritis: a post-hoc analysis on cartilage and non-cartilaginous tissue alterations in a randomized controlled trial.
- Authors: Roemer FW, Aydemir A, Lohmander S, Crema MD, Marra MD, Muurahainen N, Felson DT, Eckstein F, Guermazi A
- Issue date: 2016 Jul 9
- Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.
- Authors: Eckstein F, Hochberg MC, Guehring H, Moreau F, Ona V, Bihlet AR, Byrjalsen I, Andersen JR, Daelken B, Guenther O, Ladel C, Michaelis M, Conaghan PG
- Issue date: 2021 May 7